Mirna to Evaluate Silence Delivery Technologies for microRNA Drug Candidates | GenomeWeb

By Doug Macron

Silence Therapeutics this week announced that it has signed a deal under which Mirna Therapeutics will evaluate two of its proprietary delivery technologies for use with Mirna's therapeutic microRNA mimics.

The agreement marks the second such deal in as many months for Silence as it works to leverage its technologies for applications outside of its core RNAi drugs focus.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.